Moderna’s stock surged approximately 10% in after-hours trading following the announcement of a patent litigation settlement with Arbutus Biopharma and Genevant Sciences. Moderna will pay $950 million in Q3, incurring the charge in Q1, and will not owe any future royalties.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Moderna surges after hours on patent settlement with Arbutus and Genevant (MRNA:NASDAQ)
Moderna’s stock surged approximately 10% in after-hours trading following the announcement of a patent litigation settlement with Arbutus Biopharma and Genevant Sciences. Moderna will pay $950 million in Q3, incurring the charge in Q1, and will not owe any future royalties.